InflaRx (NASDAQ:IFRX) Earns Buy Rating from Analysts at Needham & Company LLC

Key Points

• Needham & Company initiated coverage of InflaRx with a Buy rating and an $8.00 price target, implying potential upside of 282.78% from the prior close.
• Analyst sentiment is generally positive: InflaRx has an overall “Moderate Buy” consensus rating and an average price target of $7.43, though ratings range from Strong Buy to Sell.
• InflaRx reported a quarterly loss of $0.11 per share, missing the $0.07 consensus estimate. The clinical-stage biotech focuses on complement-system therapies, including its lead candidate vilobelimab.

Stock analysts at Needham & Company LLC began coverage on shares of InflaRx (NASDAQ:IFRX - Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $8.00 price target on the stock. Needham & Company LLC's price target would suggest a potential upside of 282.78% from the company's previous close.

IFRX has been the subject of several other research reports. Cantor Fitzgerald lifted their price target on shares of InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a report on Wednesday, June 24th. Finally, Zacks Research lowered InflaRx from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $7.43.

InflaRx Stock Performance

NASDAQ:IFRX opened at $2.09 on Monday. The company has a market cap of $308.00 million, a price-to-earnings ratio of -3.60 and a beta of 2.52. InflaRx has a twelve month low of $0.80 and a twelve month high of $2.95. The stock has a fifty day simple moving average of $2.00 and a 200-day simple moving average of $1.75.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.04). As a group, equities research analysts predict that InflaRx will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC increased its position in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after buying an additional 7,616 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in InflaRx in the second quarter worth about $25,000. Boothbay Fund Management LLC grew its stake in shares of InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company's stock worth $235,000 after acquiring an additional 17,056 shares during the last quarter. AXQ Capital LP acquired a new position in shares of InflaRx during the second quarter valued at about $41,000. Finally, Eversept Partners LP increased its holdings in shares of InflaRx by 1.5% during the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company's stock valued at $1,775,000 after acquiring an additional 26,677 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.